Patel Naimish 4

What Happened
Naimish Patel, Chief Medical Officer of CRISPR Therapeutics (CRSP), made an open-market purchase of 1,508 common shares on April 3, 2025 at $32.96 per share, for a total value of about $49,704. This filing reports a purchase (code P), which is a direct acquisition rather than a sale or award.

Key Details

• Transaction date and price: April 3, 2025 — 1,508 shares at $32.96 each (~$49,703.68 / $49,704).
• Shares owned after transaction: Not disclosed in this Form 4.
• Footnote: The purchase was matchable under Section 16(b) to a subsequent sale of the same 1,508 shares on May 29, 2025 (a mandatory "sell to cover" tied to vested RSUs). Patel agreed to remit $4,493.84 to the issuer, representing the full short-swing profit. The sale was reported separately on a Form 4 filed May 30, 2025.
• Filing timeliness: The Form 4 was filed Jan 27, 2026 for a transaction dated Apr 3, 2025; this indicates a late filing.

Context
Purchases by executives are often watched by investors as potential signals of confidence, but motivations are not disclosed in the filing. The footnote clarifies this purchase was later matched to a required sell-to-cover related to vested RSUs and resulted in a Section 16(b) short-swing disposition remedy (payment of profit back to the company).